RUA Life Sciences’ AGM statement and trading update demonstrated good progress across its businesses since the FY 2021 results announcement earlier in the summer. RUA’s product that is closest to the market – the large bore vascular graft – is back on track for a Q1 2022 commercial launch. The 510(k) approval and agreements with distribution partners will likely result in an increase in our valuation when they occur.
01 Sep 2021
Confident AGM And Trading Update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Confident AGM And Trading Update
RUA Life Sciences Plc (RUA:LON) | 10.2 -0.1 (-4.7%) | Mkt Cap: 6.36m
- Published:
01 Sep 2021 -
Author:
Hannah Crowe | Andy Smith -
Pages:
4
RUA Life Sciences’ AGM statement and trading update demonstrated good progress across its businesses since the FY 2021 results announcement earlier in the summer. RUA’s product that is closest to the market – the large bore vascular graft – is back on track for a Q1 2022 commercial launch. The 510(k) approval and agreements with distribution partners will likely result in an increase in our valuation when they occur.